LGM
ELDN icon

Logos Global Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Logos Global Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,339,793
Closed -$5.91M – 52
2021
Q4 		$5.91M Hold
1,339,793
– – 0.61% 37
2021
Q3 		$8.28M Hold
1,339,793
– – 0.6% 33
2021
Q2 		$10.6M Buy
1,339,793
+1,115,722
+498% +$10.5M 0.89% 35
2021
Q1 		$2.4M Hold
224,071
– – 0.23% 47
2020
Q4 		$3.45M Buy
+224,071
New +$4.27M 0.3% 45

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Logos Global Management's ELDN Position: Q1 2022 in Review

Logos Global Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2022, closing a stake of 1,339,793 shares — an estimated $5.91M sold.

Logos Global Management first reported a position in ELDN in Q4 2020 and held it in 5 quarters. The position peaked at $10.6M in Q2 2021. 32 funds tracked by Wall St. Rank hold ELDN as of Q1 2022.

  • Logos Global Management reported no remaining Eledon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 1,339,793 Eledon Pharmaceuticals shares in Q1 2022, an estimated $5.91M.
  • Logos Global Management first reported a position in Eledon Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Logos Global Management's Eledon Pharmaceuticals position peaked at $10.6M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.